Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection

Antiviral Therapy

Volumn 10, Issue 1, 2005, Pages 13-28

  Wainberg, Mark A ^a   Sawyer, James P C ^b   Montaner, Julio S G ^c   Murphy, Robert L ^d   Kuritzkes, Daniel R ^e   Raffi, Francois ^f  

^a MCGILL UNIVERSITY   (Canada)

^b Prism Ideas   (United Kingdom)

^c ST PAUL S HOSPITAL   (Canada)

^d NORTHWESTERN UNIVERSITY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; ABACAVIR; AMDOXOVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; ELVUCITABINE; EMTRICITABINE; ENFUVIRTIDE; FIALURIDINE; LAMIVUDINE; MITOCHONDRIAL DNA; NEW DRUG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPD 754; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG RESEARCH; DRUG SUBSTITUTION; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LEUKOCYTE COUNT; LIPODYSTROPHY; LIVER FAILURE; MITOCHONDRIAL MYOPATHY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; BIOASSAY; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; DRUG INTERACTION; DRUG TOLERANCE; GENETICS; METHODOLOGY; MUTATION; SAFETY; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG TOLERANCE; ENDPOINT DETERMINATION; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SAFETY;

EID: 18344396308     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Dybul M, Fauci AS, Bartlett JG, Kaplan JE & Pau AK; Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Annals of Internal Medicine 2002; 137(5 Pt 2):381-433.
2. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults & Adolescents. 2003. Bethesda, MD: US National Institutes of Health.
3. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritizkes DR, Fallon MA & Rubin M. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4+ cells per cubic millimetre. New England Journal of Medicine 1995; 333:1662-1669.
4. Delta Coordinating Committee. Delta: a randomised, double-blind controlled trial comparing combinations of zidovudine plus ddI or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348:283-291.
5. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS & Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200-500 per millimetre. New England Journal of Medicine 1996; 335:1081-1090.
6. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338:853-860.
7. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR & Nemo GJ; Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of Internal Medicine 2001; 135:17-26.
8. Tamalet C, Fantini J, Tourres C & Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 2003; 17:2383-2388.
9. Lundgren JD, Ledergerber B, Fusco GP, Weber R, Reiss P, Castelli F, Staszewski S, Hogg R, Walker AS, Petoumenos K, D'Arminio Monforte A, Mussini C, Lamoe F, Gill MJ & Phillips AN. Risk of death following triple class virological failure: the PLATO Collaboration. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract H-450.
10. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS & Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV New England Journal of Medicine 2002; 347:385-394.
11. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D & Routy JP. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-F23.
12. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G & Kucherer C. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. Antiretroviral Therapy 2001; 26:266-273.
13. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. British Medical Journal 2001; 322:1087-1088.
14. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP & Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. Journal of the American Medical Association 2002; 288:181-188.
15. Food and Drug Administration. Guidance for Industry: Antiretroviral Drugs using Plasma HIV RNA Measurements - Clinical Considerations for Accelerated and Traditional Approval. 2002. Rockville, MD: Food and Drug Administration.
16. Wainberg MA & Montaner JSG. Emerging challenges in the clinical testing of new drugs for HIV disease. International Antiviral News 1998; 6:224-226.
17. Robbins BL, Srinivas RV, Kim C, Bischofberger N & Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2- phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrobial Agents er Chemotherapy 1998; 42:612-617.
18. Tisdale M, Kemp SD, Parry NR & Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1993; 90:5653-5656.
19. Cahn P, Raffi F, Saag M, Wolff M, Pearce D, Molina JM, Borroto-Esoda KE, Shaw AL, Hinkle JE, Waters JM, Mondo E, Quinn JB & Rousseau G for the FTC-301 Study Team. Virologic efficacy and patterns of resistance mutations in ART-naive patients receiving combination therapy with once-daily emtricitabine compared to twice daily stavudine in a randomized, double-blind, multi-center clinical trial. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract P606.
20. Descamps D, Flandre P, Calvez V, Peytavin, G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F & Brun-Vézinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. Journal of the American Medical Association 2000; 283:205-211.
21. Maguire M, Gartland M, Moore S, Hill A, Tisdale M, Harrigan R & Kleim JP. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/ lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS 2000; 14:1195-1201.
22. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, Morlat P, Journot V, Decazes JM & Chene G. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 2000; 182:599-602.
23. Rousseau FS, Kahn JP, Thompson M, Mildavan D, Shepp D, Sommadossi JP, Delehanty J, Simpson JN, Wang LH, Quinn JB, Wakeford C & van der Horst C. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). Journal of Antimicrobial Chemotherapy 2001; 48:507-513.
24. Van der Horst C, Sanne I, Wakeford C, Quinn J & Rousseau F. Two randomised controlled equivalence trials on emtricitabine (FTC) to lamivudine (3TC). 8th Annual Conference on Retroviruses & Opportunistic Infections. 4-8 February 2001, Chicago, IL, USA. Abstract 18.
25. Saag M, Cahn P, Raffi F, Wolff M, Pearce D, Molina J, Hinkle J, Shaw A, Quinn J & Rousseau F. A randomised, double-blind, multicentre comparison of emtricitabine Qd to stavudine bid. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. 27-30 September 2002, San Diego, CA, USA. Abstract LB-1.
26. Raffi F, Saag M, Cahn P, Wolff M, Pearce D, Molina J, Hinkle J, Shaw A, Mondou E, Quinn J & Rousseau F. A randomised, double-blind, multi-centre comparison of emtricitabine QD to stavudine BID in treatment-naive HIV-infected patients. Antiviral therapy 2003; 8:S193.
27. Rousseau FS, Wakeford C, Mommeja-Marin H, Sanne I, Moxham C, Harris J, Hulett L, Wang LH, Quinn JB & Barry DW; FTC-102 Clinical Trial Group. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. Journal of Infectious Diseases 2003; 188:1652-1658.
28. Shaw AL, Shen G, Wakeford CW, Quinn JB & Rousseau FS. Once-daily emtricitabine compared to twice-daily abacavir within a HAART regimen in antiretroviral drug-naive HIV-1 infected patients (ODECTA). Antiviral Therapy 2003; 8:S331.
29. Molina J, Ferchal F, Journot V, Yeni P, Rozenbaum W, Rancinan C, Moarnad-Joubert L, Fournier S, Morlat P, Dupont B, Delfraissy J, Dellamonica P, Poizot Martin I, Rozenthal E & Chêne G for the the Alize Study Group. Emtricitabine, didanosine and efavirenz once-daily (OD) versus continued PI-based HAART (C) in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial (ALIZE-ANRS99). Antiviral Therapy 2003; 8:S193.
30. Wakeford C, Shen G, Hulett L, Quinn JB & Rousseau F. Long-term efficacy and safety of emtricitabine (FTC) in HIV+ adults switching from a lamivudine (3TC)-containing HAART regimen. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 550.
31. Otto MJ, Arastèh K, Kreckel P. Sustained anti-HIV-1 effect of racivir combined with D4T and Sustiva following a 14-day treatment of infected volunteers. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract P552.
32. Dunkle LM, Oshana SC, Cheng Y-C, Hertogs K & Rice WG. ACH-126,443: a new nucleoside analog with potent activity against wild-type and resistant HIV-1 and a promising pharmacokinetic and mitochondrial toxicity profile. 8th Annual Conference on Retroviruses & Opportunistic Infections. 4-8 February 2001, Chicago, IL, USA. Abstract 303.
33. Dunkle LM, Gathe JC, Pedevillano DE, Oshana SC, Pottage JC & Rice WG. ACH-126,443 (β-L-Fd4C) shows potent anti-HIV activity in proof-of-principle study in treatment-experienced patients with M184V and other reverse transcriptase mutations [Abstract 069]. Antiviral Research 2002; Suppl.:83.
34. Dunkle LM, Gathe JC, Pedevillano DE, Robison HG, Rice WG & Pottage JC Jr. Elvucitabine: potent antiviral activity demonstrated in multi-drug resistant HIV infection. Antiviral Therapy 2003; 8:S5.
35. Fabrycki J, Zhao Y, Wearne J, Sun Y, Argarwal A, Deshpande M, Rice W & Huang M. In vitro induction of HIV variants with reduced susceptibility to elvucitabine (ACH-126,443, β-L-Fd4C). Antiviral Therapy 2003; 8:S8.
36. Gu Z, Nguyen-Ba N, Ren C, De Muys J-M, Taylor D, McKenna P, Wainberg MA & Bethell RC. Novel cytidine analogue BCH10618 is active against different clades and types of drug-resistant HIV. 1st International AIDS Society Conference. 8-11 July 2001, Buenos Aires, Argentina. Abstract 244.
37. Gu Z, Nguyen-Ba N, Mellors J, Fortier C & Wainberg M. In vitro selection and characterisation of HIV-1 resistance to BCH-10618. 8th Annual Conference on Retroviruses & Opportunistic Infections. 4-8 February 2001, Chicago, IL, USA. Abstract 472.
38. Bethell RC, Parkin N & Lie Y. Antiviral activity of SPD754 against clinical isolates of HIV-1 resistant to other NRTIs. Antiviral Therapy 2003; 8:S6.
39. Cahn P, Lange J, Cassetti I, Sawyer J, Zala C, Rolon M, Bologna R & Shiveley L. Antiviral HIV-1 activity of SPD754, a new NRTI: results of a 10 day monotherapy study in treatment naive HIV patients. 2nd International AIDS Society Conference on HIV Pathogenesis & Treatment. 13-16 July 2003, Paris, France. Abstract LB15.
40. Kim EY, Vrang L, Oberg B & Merigan TC. Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants. AIDS Research & Human Retroviruses 2001; 17:401-407.
41. Katlama C, Ghosn J, Tubiana R, Wirden M, Valantin M-A, Harmenberg J, Mårdh G, Öberg B & Calvez V. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study. AIDS 2004; 18:1299-1304.
42. Schinazi RF, Mellors J, Bazmi H, Diamond S, Garber S, Gallagher K, Geleziunas R, Klabe R, Pierce M, Rayner M, Wu JT, Zhang H, Hammond J, Bacheler L, Manion DJ, Otto MJ, Stuyver L, Trainor G, Liotta DC & Erickson-Viitanen S. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrobial Agents & Chemotherapy 2002; 46:1394-1401.
43. Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF & Erickson-Viitanen S. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′,3′- dideoxy-2′,3′-didehydro-5-fluorocytidine (Reverset). Antiviral Chemistry & Chemotherapy 2003; 14:49-59.
44. Murphy RL, Schürmann D, Beard A, Cartee L, Schinazi RF & Otto MJ. Tolerance and potent anti-HIV-1 activity of Reverset following 10 days of mono-therapy in treatment-naive individuals. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 137.
45. Stuyver LJ, McBrayer TR, Schurmann D, Kravec I, Beard A, Cartee L, Schinazi RF, de la Rosa A, Murphy RL & Otto MJ. Potent antiviral effect of Reverset™ in HIV-1 infected adults following a single oral dose. Antiviral Therapy 2004; 9:529-536.
46. Decks S, Kessler H, Eron J, Thompson M, Raffi F, Jacobson J, Sista N, Bigley J & Rousseau F. Short-term monotherapy of DAPD in HIV-infected patients. Antiviral Therapy 2000; 5(Suppl 3):7.
47. Eron JJ, Kessler H, Thompson M, Decks S, Arduino R, Jacobsen J, Sista N, Quinn J, Harris J, Bigley J & Rosseau F. Clinical HIV suppression after short-term monotherapy with DAPD. 40th Interscience Conference on Antimicrobial Agents & Chemotherapy. 17-20 September 2000, Toronto, ON, Canada. Abstract 690.
48. Mewshaw JP, Myrick FT, Wakefield DA, Hooper BJ, Haris JL, McCreedy B & Borroto-Esoda K. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. Journal of Acquired Immune Deficiency Syndromes 2002; 29:11-20.
49. Thompson M, Richmond G, Kessler H, Bae A, Sorbel J, Sista N, Adda N & Rousseau F. Preliminary results of dosing of amdoxovir in treatment-experienced patients. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 554.
50. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999; 4:87-94.
51. Margot NA, Isaacson E, McGowan I, Cheng A & Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. Journal of Acquired Immune Deficiency Syndromes 2003; 33:15-21.
52. Miller MD, Margot NA, McColl DJ, Wrin T, Coakley DF & Cheng AK. Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine in combination with lamivudine and efavirenz. Antiviral Therapy 2003; 8:S151.
53. Elion R, Cohen C, DeJesus E, Redfield R, Gathe J, Hsu R, Yau L, Ross L, Ha B, Lanier R & Scott T; COL40263 Study Team. COL40263: resistance and efficacy of once-daily Trizivir and tenofovir of in antiretroviral naive subjects. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 53.
54. Parikh U, Koontz D, Sluis-Cremer N, Hammond J, Bacheler L, Schinazi R & Mellors J. A multinucleoside resistance mutation of increasing prevalence exhibits bidirectional phenotypic antagonism with TAM. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 54.
55. Bacheler L, Vermeiren H, McKenna P, Van Houtee M & LeClerq P. Trends in genotypic and phenotypic HIV-1 drug resistance among recent clinical samples submitted for resistance testing. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract H-917.
56. Gallant JE, Rodriguez AE, Weinberg W, Young B, Berger D, Lim M, Liao Q, Rosss L, Johnson J & Shaeffer MS. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract H-1722A.
57. Hoogewerf M, Regez RM, Schouten WE, Weigel HM, Frissen PH & Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003; 362:1979-1980.
58. Jemsek J, Hutcherson P & Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 51.
59. Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D & Nelson M. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004; 18:949-951.
60. Roge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J & Gerstoft J. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antiviral Therapy 2003; 8:173-182.
61. Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Clinical Development of Medicinal Products for Treatment of HIV Infection. 2003. London: European Agency for the Evaluation of Medicinal Products.
62. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JF, Straus SE & Hoofnagle JH. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 1995; 333:1099-1105.
63. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ & Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. Journal of Infectious Diseases 2002; 185:599-607.
64. Gathe J, Kohlbrenner VM, Pierone P, Arasteh K, Rubio R, LaLonde R, Piliero P, McCallister S, Garfinkel S, Chaves R, Mukwaya GM, Dohnanyi C, Shaw S, Drees U & Mayers D. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 179.
65. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK & the Study 902 Team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
66. Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A & Bilello JA. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrobial Agents & Chemotherapy 2002; 46:464-470.
67. Sanne L, Anderson J, Kargl D, Wakeford C, Quinn JB, Moxham C & Rousseau F for the MKC-401 Study Team. Evaluation of emtricitabine within a triple NRTI HAART regimen. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-1 7 September 2003, Chicago, IL, USA. Abstract H-868.
68. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuntzkes DR, Eron JR, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J & Salgo M for the TORO1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine 2003; 348:2175-2185.
69. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraisy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M & the TORO2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New England Journal of Medicine 2003; 348:2186-2195.
70. Campbell TB, Young RK, Johnson SC, Lanier ER & Kuritzkes DR. Antiviral activity of lamivudine in persons infected with HIV-1 that has M184V and multiple thymidine analogue mutations. Antiviral Therapy 2003; 8:S156.
71. Quan Y, Brenner BG, Oliveira M & Wainberg MA. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrobial Agents & Chemotherapy 2003; 47:747-754.
72. Diallo K, Götte M & Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 2003; 47:3377-3383.
73. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS & Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. Journal of Infectious Diseases 2003; 188:992-1000.
74. Eshleman SH & Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Reviews 2002; 4:59-63.
75. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW & Leonard JM. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrobial Agents & Chemotherapy 1997; 41:654-660.
76. Zala C, Patterson P, Coll P, Bouzas MB, Kaufman S, Gun A, Perez H & Cahn P. Virological response and safety at 48 weeks of double-boosted protease inhibitors with lopinavir/r plus either saquinavir or amprenavir in heavily pretreated HIV infected patients. 14th International AIDS Conference. 7-12 July 2002, Barcelona, Spain. Abstract TuPeB4492.
77. Staszewski S, Dauer B, Von Hentig N, Muller A, Stephan C, Carlebach A, Mosch M, Gute P, Klauke S, Kurowski M & Sturmer M. The LOPSAQ Study: 24-week analysis of the double protease inhibitor (PI) salvage therapy regimen containing lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy. Antiviral Therapy 2003; 8:S342.
78. Stavudine Data Sheet. Bristol-Myers Squibb USA. June 2004.
79. Zidovudine Data Sheet. GlaxoSmithKline USA. April 2003.
80. Barry M, Mulcahy F, Merry C, Gibbons S & Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clinical Pharmacokinetics 1999; 36:289-304.
81. Kearney BP, Isaacson E, Sayre J, Ebrahimi R & Cheng AK. The pharmacokinetics of abacavir, a purine nucleoside, are not affected by tenofovir DF. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract A-1615.
82. Landman R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalisherif A, Trylesinski A, Katlama C, Girard PM, Raffi F, Yeni P, Bentata M, Jarrousse B, Michelet C, Flandre P & Tonus study group. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus Study. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 52.
83. Kearney B, Flaherty J, Sayre J, Wolf J & Coakley D. A multiple dose randomized crossover drug interaction study between tenofovir DF and lamivudine or didanosine. 1st International AIDS Society Conference on HIV Pathogenesis & Treatment. 8-11 July 2001, Buenos Aires, Argentina. Abstract 337.
84. Gilead Sciences, Inc. Letter to Healthcare Providers. 14 October 2003.
85. Kaul S, Bassi K, Damle B, Xie J, Gale J, Kearney B & Hanna G. Pharmacokinetic evaluation of the combination of atazanavir (ATZ), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate for a once-daily antiretroviral regimen. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract A-1616.
86. Bethell R, Adams J, De Muys J, Lippens J, Richard A, Hamelin B, Ren C, Collins P, Struthers-Semple C, Holdich T & Sawyer J. Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. 11th Conference on Retroviruses & Opportunistic Injections. 8-11 February 2004, San Francisco, CA, USA. Abstract 138.
87. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clinical Therapeutics 2000; 22:685-708.
88. White AL. Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections 2001; 77:158-173.
89. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV & Montaner JS. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine 2002; 346:811-820.
90. Moyle GM. Lipid abnormalities during ART: it's the drug, not the class. AIDS Reader 2004; 14:15-16, 20-22.